eYugoslavia.comBiogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select …Victoria Times ColonistToday Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) announced additional results from the SELECT Phase 2b trial, the first of two r…
Biogen Idec e Abbott presentano i risultati positivi relativi all'esperimento …ANSA.itOggi Biogen Idec (NASDAQ: BIIB) e Abbott (NYSE: ABT) hanno presentato ulteriori risultati dalla fase 2b dello studio SELECT, il primo di due studi per la regist…
Abbott Touts $4 Billion in Drug Sales as It Pitches SpinoffBusinessWeekDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business wi…
Abbott Touts $4 Billion in New Drug Sales as It Pitches SpinoffBloombergDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business w…
USA TodayAbbott Executive Sees Some Pipeline Drugs With Yearly Sales Over $1BWall Street JournalHowever, several of these drugs, including daclizumab, may not make it to market until around 2015, assuming successful clinical trials and regulatory appro…
JPMorgan Chase & Co. (JPM) Analysts Reiterate a "Neutral" Rating on Biogen …LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interfero…
Abbott May Be Doing The Right Thing At The Wrong TimeSeeking AlphaBeyond that is a joint venture with Biogen Idec (BIIB) for daclizumab in the increasingly-crowded next-gen multiple sclerosis space and a slate of Hep C drugs that don't seem so obvi…
The Zacks Analyst Blog Highlights: Abbott Labs, Bristol-Myers Squibb, Biogen …PR Newswire (press release)Abbott Labs, along with partner Biogen (Nasdaq: BIIB), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple …
USA TodayAbbott Laboratories' CEO Discusses Q3 2011 Results – Earnings Call TranscriptSeeking AlphaDaclizumab, our next generation biologic for MS is in Phase III development. Our recently announced results from our Phase II registrational trial su…
Deutsche Bank (DB) Analysts Reiterate a "Buy" Rating on Biogen Idec (BIIB)LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1…